Overview

A Study of Haploidentical Bone Marrow Transplant for Patients With Hematologic Malignancies

Status:
Suspended
Trial end date:
2021-07-01
Target enrollment:
Participant gender:
Summary
The primary objective is to determine overall survival 180 days after transplantation involving HLA-haploidentical stem cell/bone marrow graft, and post-transplant Cy.
Phase:
Phase 2
Details
Lead Sponsor:
University of California, San Diego
Treatments:
Cyclophosphamide